Palliative first-line treatment with weekly high-dose 5-fluorouracil as 24h-infusion and gemcitabine in metastatic pancreatic cancer (UICC IV)

Medical Science Monitor

Volumn 16, Issue 3, 2010, Pages

  Roehrig, Sandra ^a   Wein, Axel ^a   Albrecht, Heinz ^a   Konturek, Peter C ^a   Reulbach, Udo ^b   Männlein, Gudrun ^a   Wolff, Kerstin ^a   Ostermeier, Nicola ^a   Hohenberger, Werner ^b   Hahn, Eckhart G ^a   Boxberger, Frank ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Gemcitabine; Palliative first line treatment; Pancreatic cancer; Weekly high dose 5 FU as 24h infusion

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DEXAMETHASONE; ERLOTINIB; FLUOROURACIL; GEMCITABINE; GRANISETRON; LOPERAMIDE; OXALIPLATIN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASCITES; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DISTANT METASTASIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCORTICOGRAPHY; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERBILIRUBINEMIA; HYPONATREMIA; INFECTION; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PANCREAS CANCER; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOEMBRYONIC ANTIGEN; CLINICAL TRIALS, PHASE II AS TOPIC; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 77649266239     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. und das RKI: Krebs in Deutschland 2003-2004. Häufigkeiten und Trends. Berlin, 2008; 38-41
2. Gralow J, Ozols RF, Bajorin DF et al: Clinical cancer advances 2007: major research advances in cancer treatment, prevention and screening - a report from the American Society of Clinical Oncology. J Clin Oncol, 2008; 26: 313-25
3. Schmoll H, Höffken K, Possinger K (eds.): Kompendium Internistische Onkologie, Teil 2. Heidelberg, Springer Medizin Verlag, 2006; 3975-76
4. Adler G, Seufferlein T, Bischoff SC et al: S3-Guidelines "Exocrine pancreatic cancer" 2007. Z Gastroenterol; 2007; 45: 487-523
5. Burris HA, Moore MJ, Andersen J et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomised trial. J Clin Oncol, 1997; 15: 2403-13
6. Heinemann V, Quietzsch D, Gieseler F et al: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol, 2006; 24: 3946-52
7. Colucci G, Giuliani F, Gebbia V et al: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer, 2002; 94: 902-10
8. Louvet C, Labianca R, Hammel P et al: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol, 2005; 23: 3509-16
9. Rocha Lima CM, Green MR, Rotche R et al: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol, 2004; 22: 3776-83
10. Berlin JD, Catalano P, Thomas JP et al: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol, 2002; 15: 3270-75
11. Herrmann R, Bodoky G, Ruhstaller T et al: Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol, 2007; 25: 2212-17
12. Bramhall SR, Schulz J, Nemunaitis J et al: A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitbine and placebos as first line therapy in patients with advanced pancreatic cancer. Br J Cancer, 2002; 87: 161-67
13. Van Cutsem E, van de Velde H, Karasek P et al: Phase III Trial of Gemcitabine Plus Tipifarnib Compared with Gemcitabine Plus Placebo in Advanced Pancreatic Cancer. J Clin Oncol, 2004; 22: 1430-38
14. Spano JP, Chodkiewicz C, Maurel J et al: Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet, 2008; 371: 2101-8
15. Moore MJ, Goldstein D, Hamm J et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 2007; 25: 1960-66
16. Talar-Wojnarowska R, Malecka-Panas E: Molecular pathogenesis of pancreatic adenocarcinoma: Potential clinical implications. Med Sci Monit, 2006; 12(9): RA186-93
17. Wein A, Wehler M, Fischer B et al: Phase II study with weekly 24-hour infusion (24-h inf.) of high-dose 5-fluorouracil (5-FU) and gemcitabine (GEM) in metastatic pancreas cancer (UICC IVb): final results. Proc Am Soc Clin Oncol, 2002; 21: 620
18. Sultana A, Smith CT, Cunningham D et al: Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol, 2007; 25: 2607-15
19. Sultana A, Smith CT, Cunningham D et al: Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer, 2008; 99: 6-13
20. Heinemann V, Labianca R, Hinke A, Louvet C: Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a german multicenter study. Ann Oncol, 2007; 18: 1652-59
21. Plunkett W, Huang P, Gandhi V: Preclinical characteristics of gemcitabine. Anticancer Drugs, 1995; 6: 7-13
22. Heinemann V, Xu YZ, Chubb S et al: Inhibition of Ribonucleotide Reduction in CCRF-CEM Cells by 2′,2′-Difluorodeoxycytidine. Mol Pharmacol, 1990; 38: 567-72
23. Rothenberg ML, Moore MJ, Cripps MC et al: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol, 1996; 7: 347-53
24. WHO: WHO Handbook for Reporting Result of Cancer Treatment. Offset Publication, vol 48. Geneva, World Health Organisation, 1979
25. Greenwood M: The Natural Duration of Cancer. Rep. Publ. Hlth. Med. Subj., No. 33. London: HM Stationary Office, 1926
26. Wagner AD, Buechner-Steudel P, Wein A et al: Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Ann Oncol, 2007; 18: 82-87
27. Berlin JD, Adak S, Vaughn DJ et al: A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296). Oncology, 2000; 58: 215-18
28. Cascinu S, Silva RR, Barni S et al: A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer, 1999; 80: 1595-98
29. Hidalgo M, Castellano D, Paz-Ares L et al: Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol, 1999; 17: 585-92
30. Kurtz JE, Kohser F, Négrier S et al: Gemcitabine and protracted 5-FU for advanced pancreatic cancer. A phase II study. Hepatogastroenterology, 2000; 47: 1450-53
31. Matano E, Tagliaferri P, Libroia A et al: Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study. Br J Cancer, 2000; 82: 1772-75
32. Rauch DP, Maurer CA, Aebi S et al: Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer. Oncology, 2001; 60: 43-48
33. Barone C, Cassano A, Corsi DC et al: Weekly gemcitabine and 24-hour infusional 5-fluorouracil in advanced pancreatic cancer: a phase I-II study. Oncology, 2003; 64: 139-45
34. Cunningham D, Chau I, Stocken D et al: GEM-CAP Phase III randomised comparison of gemcitabine with gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Eur J Cancer, 2005; 3: 12
35. Bernhard J, Dietrich D, Scheithauer W et al: Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial - SAKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol, 2008; 26: 3695-701
36. Philip PA, Benedetti J, Fenoglio-Preiser C et al: Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. Proc Am Soc Clin, 2007; 25: 4509
37. Kindler HL, Niedzwiecki D, Hollis D et al: A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB). Proc Am Soc Clin, 2007; 25: 4508
38. Boeck S, Hinke A, Wilkowski R, Heinemann V: Importance of performance status for treatment outcome in advanced pancreatic cancer. World J Gastroenterol, 2007; 13: 224-27
39. Giaginis C, Katsamangou E, Tsourouflis G et al: Peroxisome proliferator-activated receptor-gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: association with clinicopathological parameters, tumor proliferative capacity, and patients' survival. Med Sci Monit 2009;15(5): BR148-56
40. Boeck S, Heinemann V: Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer. J Clin Oncol, 2008; 26: 1178-79